Abstract |
We assessed T-cell responses in young osteosarcoma patients vaccinated with 105AD7, 1-6 months after having received chemotherapy. 105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein that protects from attack by complement and which is overexpressed on osteosarcoma cells. Seven out of 21 investigated patients made a IFN-gamma T-cell response against the vaccine, 105AD7 as assessed by ELISPOT. Cytokine secretion was analysed using Luminex assays and revealed TNF-alpha and GM-CSF responses not only to the vaccine but also towards the native antigen, CD55, in 5 / 14 (36%) of investigated patients. Importantly, the Luminex assay was found to be more sensitive than the more established T-cell assays (ELISPOT and proliferation assay), since responses towards the native antigen were recorded in this assay. Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment.
|
Authors | G J Ullenhag, I Spendlove, N F S Watson, C Kallmeyer, K Pritchard-Jones, L G Durrant |
Journal | Clinical immunology (Orlando, Fla.)
(Clin Immunol)
Vol. 128
Issue 2
Pg. 148-54
(Aug 2008)
ISSN: 1521-7035 [Electronic] United States |
PMID | 18508409
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 105AD7 antibody
- Antibodies, Anti-Idiotypic
- Antibodies, Monoclonal
- CD55 Antigens
- Cancer Vaccines
- Tumor Necrosis Factor-alpha
- Interferon-gamma
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- Antibodies, Anti-Idiotypic
(administration & dosage, immunology)
- Antibodies, Monoclonal
(administration & dosage, immunology)
- Bone Neoplasms
(immunology)
- CD55 Antigens
(immunology)
- Cancer Vaccines
(administration & dosage, immunology)
- Cell Proliferation
- Granulocyte-Macrophage Colony-Stimulating Factor
(biosynthesis, immunology)
- Humans
- Immunization, Passive
- Immunoenzyme Techniques
- Injections, Intramuscular
- Injections, Subcutaneous
- Interferon-gamma
(biosynthesis, immunology)
- Osteosarcoma
(immunology)
- T-Cell Antigen Receptor Specificity
- T-Lymphocytes
(immunology, metabolism)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(biosynthesis, immunology)
- United Kingdom
|